VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

EHA 2015 | Update on the efficacy and safety of tyrosine kinase inhibitors for chronic myeloid leukemia

At the 20th Congress of the European Hematology Association (EHA), Giuseppe Saglio, MD, of the University of Turin, Turin, Italy, discusses the latest clinical trial results of tyrosine kinase inhibitors (TKIs) for the treatment of patients with chronic myeloid leukemia. As therapeutic strategies with TKIs continue to improve patient outcomes, the importance of monitoring and optimally managing patients is emphasized.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter